EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

A systematic review and meta‐analysis of neoadjuvant imatinib use in locally advanced and metastatic gastrointestinal stromal tumors

Timothy Jia Rong Lam, Shamill Amedot Udonwa, Yoshio Masuda iD, Mark Hao Xuan Yeo, Mohamad Farid Bin Harunal Ras, Brian K P Goh

World Journal of Surgery · 2024-07 · 48 (7) · 1681-1691

DOI: 10.1002/wjs.12210 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift World Journal of Surgery, online erschienen am 17.05.2024. Verfasst von Timothy Jia Rong Lam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Imatinib Mesylate, Neoadjuvant Therapy, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Several doubts remain regarding the optimal use of neoadjuvant imatinib in gastrointestinal stromal tumors (GISTs), such as ideal treatment duration, patient selection, and long‐term survival outcomes. This manuscript provides a comprehensive review on neoadjuvant imatinib treatment outcomes and facilitate evidence‐based decision‐making for the use of imatinib therapy in GISTs.

Methods

Four databases (PubMed, EMBASE, Scopus, and Cochrane Library) were searched from inception to September 9, 2023. Meta‐analyses of proportions were performed for the outcomes of R0 resection, disease responses, and 1‐year, 3‐year, and 5‐year overall survival (OS) as well as 1‐year, 3‐year, and 5‐year disease free survival (DFS). Sensitivity analyses in the form of leave‐one‐out analyses, meta‐regression, and subgroup analyses were performed for outcomes with substantial statistical heterogeneity.

Results

The search yielded 1254 articles, and 36 studies were included in our analysis. Meta‐analysis of proportions revealed that 1‐year, 3‐year, and 5‐year OS was 100%, 94%, and 88%, while 1‐year, 3‐year and 5‐year DFS was 99%, 89%, and 79%, respectively. An R0 resection rate of 89% and a disease response rate of 67% was achieved after a mean duration of treatment of 8.41 ± 0.367 months. KIT exon 9 mutation was significantly associated with poorer 5‐year DFS.

Conclusion

This study quantified key outcomes for neoadjuvant imatinib in locally advanced and metastatic or recurrent GIST. Patients with gastric and rectal tumous stand to benefit from neoadjuvant imatinib with an optimal treatment duration of 8 months. Furthermore, the potential utility of mutational analysis in guiding treatment with neoadjuvant imatinib was demonstrated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal Stromal TumorsImatinib MesylateNeoadjuvant TherapyGastrointestinal NeoplasmsAntineoplastic AgentsHumansTreatment Outcome

Stichwörter der Autor:innen

gastrointestinal stromal tumorsimatinibmeta‐analysisneoadjuvantsystematic review

Substanzen

Imatinib MesylateAntineoplastic Agents

Autor:innen und Institutionen

  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Ministry of Health Holdings, Singapore, Singapore.
  • Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  • Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and National Cancer Centre Singapore, Singapore, Singapore.
  • Surgery Academic Clinical Programme, Duke-National University of Singapore Medical School, Singapore, Singapore.

ORCID-Profile: Yoshio Masuda

Zitieren

APA

Lam, T. J. R., Udonwa, S. A., Masuda, Y., Yeo, M. H. X., Farid Bin Harunal Ras, M., & Goh, B. K. P. (2024). A systematic review and meta‐analysis of neoadjuvant imatinib use in locally advanced and metastatic gastrointestinal stromal tumors. World Journal of Surgery, 48(7), 1681-1691. https://doi.org/10.1002/wjs.12210

Vancouver

Lam TJR, Udonwa SA, Masuda Y, Yeo MHX, Farid Bin Harunal Ras M, Goh BKP. A systematic review and meta‐analysis of neoadjuvant imatinib use in locally advanced and metastatic gastrointestinal stromal tumors. World Journal of Surgery. 2024;48(7):1681-1691. doi:10.1002/wjs.12210

BibTeX
@article{Lam2024,
  author = {Lam, Timothy Jia Rong and Udonwa, Shamill Amedot and Masuda, Yoshio and Yeo, Mark Hao Xuan and Farid Bin Harunal Ras, Mohamad and Goh, Brian K P},
  title = {A systematic review and meta‐analysis of neoadjuvant imatinib use in locally advanced and metastatic gastrointestinal stromal tumors},
  journal = {World Journal of Surgery},
  year = {2024},
  volume = {48},
  number = {7},
  pages = {1681--1691},
  doi = {10.1002/wjs.12210}
}
Kostenlos starten →